However, regulatory mechanism underlying these effects of Ang II blocking drugs on NAFLD remains to be unsolved and the relationship between Ang II and NLRP3 inflammasome also has not been reported. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.